With more than 20 years’ experience in the global pharmaceutical and biotechnology industry, Brent Hatzis-Schoch has held leadership positions at both commercial and development-stage companies.
Prior to joining Black Diamond as Chief Operating Officer, General Counsel, Brent was Senior Vice President (SVP), General Counsel and Corporate Secretary at Radius Health, Inc., a publicly traded commercial-stage biopharmaceutical company focused on the areas of osteoporosis and oncology. While at Radius, Brent had responsibility for the legal, intellectual property, contracts management, compliance, regulatory, and quality assurance functions, and helped build the company from a development-stage company to a commercial organization. Previously, he served as SVP and Chief Legal Counsel at Merz Pharma, an international healthcare company, in Frankfurt, Germany, where he had global responsibility for the legal, IP, and compliance functions. Brent began his legal career in private practice and later held senior legal positions in the U.S. and internationally, including as General Counsel to two publicly traded development-stage German biopharmaceutical companies, European legal counsel for Baxter International, and Associate General Counsel of Pharmacia Corporation.
Brent holds a Juris Doctor from George Washington University and was a Fulbright Scholar at the University of Cologne, Germany. He received his B.A. in International Relations from the University of Delaware.
What is Brent Hatzis-Schoch's net worth?
The estimated net worth of Brent Hatzis-Schoch is at least $31.94 thousand as of May 12th, 2021. Mr. Hatzis-Schoch owns 12,478 shares of Black Diamond Therapeutics stock worth more than $31,944 as of April 11th. This net worth estimate does not reflect any other investments that Mr. Hatzis-Schoch may own. Learn More about Brent Hatzis-Schoch's net worth.
How do I contact Brent Hatzis-Schoch?
Has Brent Hatzis-Schoch been buying or selling shares of Black Diamond Therapeutics?
Brent Hatzis-Schoch has not been actively trading shares of Black Diamond Therapeutics in the last ninety days. Most recently, Brent Hatzis-Schoch sold 4,078 shares of the business's stock in a transaction on Wednesday, May 12th. The shares were sold at an average price of $27.42, for a transaction totalling $111,818.76. Following the completion of the sale, the insider now directly owns 12,478 shares of the company's stock, valued at $342,146.76. Learn More on Brent Hatzis-Schoch's trading history.
Who are Black Diamond Therapeutics' active insiders?